<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04319224</url>
  </required_header>
  <id_info>
    <org_study_id>JTX-2011-R01</org_study_id>
    <nct_id>NCT04319224</nct_id>
  </id_info>
  <brief_title>Vopratelimab (JTX-2011) Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors</brief_title>
  <official_title>An Open-label, Multi-center, Rollover Study in Subjects With Advanced Solid Tumor Malignancies After Participation in a Vopratelimab (JTX-2011) Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jounce Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jounce Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      JTX-2011-R01 is an open label, multicenter, rollover study that is designed to provide
      continued access to vopratelimab for eligible subjects with advanced solid tumor malignancies
      who have previously participated in a vopratelimab study (the parent study).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vopratelimab is an agonist monoclonal antibody that specifically binds to the Inducible
      CO-Stimulator of T cells (ICOS) to generate an anti-tumor immune response. This is an open
      label, roll over study to evaluate the long-term safety of continued treatment with
      vopratelimab monotherapy or combination treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% subjects with adverse events (AEs)</measure>
    <time_frame>48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>% subjects with serious adverse events (SAEs)</measure>
    <time_frame>48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>% subjects with clinically significant change from baseline in clinical laboratory tests</measure>
    <time_frame>48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median progression free survival (PFS)</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Vopratelimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will continue to receive vopratelimab monotherapy per parent protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vopratelimab with ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will continue to receive vopratelimab in combination with ipilimumab per parent protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vopratelimab with nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will continue to receive vopratelimab in combination with nivolumab per parent protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vopratelimab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Vopratelimab</arm_group_label>
    <arm_group_label>Vopratelimab with ipilimumab</arm_group_label>
    <arm_group_label>Vopratelimab with nivolumab</arm_group_label>
    <other_name>JTX-2011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Vopratelimab with ipilimumab</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Vopratelimab with nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is currently receiving and tolerating vopratelimab (JTX-2011) therapy and
             receiving clinical benefit from study treatment in the opinion of the Investigator
             and/or Sponsor.

          -  Subject has demonstrated compliance with the parent study requirements, as assessed by
             the Investigator and/or Sponsor, and is able and willing to comply with the necessary
             visits and assessments as part of the rollover study.

          -  Written informed consent must be obtained prior to enrolling in the rollover study and
             receiving study treatment. If consent cannot be expressed in writing, it must be
             formally documented and witnessed, ideally via an independent trusted witness.

          -  Women of childbearing potential and males with partners of child-bearing potential
             must agree to use adequate birth control throughout their participation and for 5
             months following the last study treatment

        Exclusion Criteria:

          -  Subject was permanently discontinued from the parent study due to unacceptable
             toxicity, non-compliance with study procedures, withdrawal of consent, or any other
             reason.

          -  Subject is receiving concurrent anti-cancer treatment (excluding combination drugs
             such as nivolumab or ipilimumab as a component of the combination dosing regimen used
             in parent study).

          -  Women who are pregnant or breastfeeding.

          -  Subject has any medical or social condition that, in the opinion of the Investigator,
             might place a subject at increased risk, affect compliance, or confound safety or
             other clinical study data interpretation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen Hooper, MD, FACP</last_name>
    <role>Study Director</role>
    <affiliation>Jounce Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nancy Mota</last_name>
    <email>Vopra_Rollover@jouncetx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russell Pachynski, MD</last_name>
      <email>rkpachynski@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Russell Pachynski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Yap, MD</last_name>
      <phone>877-632-6789</phone>
    </contact>
    <investigator>
      <last_name>Timothy Yap, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>JTX-2011</keyword>
  <keyword>Vopratelimab</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>ICOS</keyword>
  <keyword>Anti-CTLA-4</keyword>
  <keyword>PD-1</keyword>
  <keyword>PD-L1</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>Cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

